Shopping Cart
Remove All
Your shopping cart is currently empty
PK095
Copy Product Info
😃Good
Catalog No. T67763Cas No. 380314-37-4
PK095 is a proprietary compound in the guanidine - based F1F0-ATPase inhibitor family.
PK095
Copy Product Info😃Good
Purity: 97.06%
Catalog No. T67763Cas No. 380314-37-4
PK095 is a proprietary compound in the guanidine - based F1F0-ATPase inhibitor family.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $62 | - | In Stock | |
| 5 mg | $146 | - | In Stock | |
| 10 mg | $207 | - | In Stock | |
| 25 mg | $331 | - | In Stock | |
| 50 mg | $457 | - | In Stock | |
| 100 mg | $617 | - | In Stock | |
| 200 mg | $826 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $148 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97.06%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
PK095 AI Summary
PK095 exhibits bioactivities across a variety of biological assays. It acts as an inhibitor of Plasmodium falciparum M18 Aspartyl Aminopeptidase with an IC50 > 73456 nM, and of Human Jumonji Domain Containing 2E with a potency of 25118.9 nM. Additionally, it inhibits Tau Fibril Formation measured by Fluorescence Polarization and Thioflavin T Binding with potencies of 22387.2 nM and 17782.8 nM, respectively. The compound also inhibits Aldehyde Dehydrogenase 1 with a potency of 39810.7 nM, Cathepsin L proteinase with an IC50 > 59642 nM, and targets the Menin-MLL Interaction in MLL-Related Leukemias with a potency of 19952.6 nM. It shows efficacy as an inhibitor of Plasmodium falciparum M17-Family Leucine Aminopeptidase with an IC50 of 1410 nM, Human alpha-Glucosidase for the cleavage of glycogen and as a potential chaperone treatment of Pompe Disease with a potency of 22387.2 nM. It acts as both an activator and inhibitor of Human alpha-Glucosidase for chaperone treatment of Pompe Disease. Furthermore, it inhibits Histone Lysine Methyltransferase G9a (35481.3 nM), Polymerase Iota (100000 nM), the malarial parasite plastid (14715.7 nM), firefly luciferase (37933 nM), and Hepatitis C Virus (11220.2 nM). The compound also inhibits NadD in a colorimetric assay with IC50 values of 15300 nM and 42400 nM, induces synthetic lethality in tumor cells producing 2HG with a potency of 29092.9 nM, and inhibits human tyrosyl-DNA phosphodiesterase 1 (TDP1) in cells in the absence (23109.3 nM) and presence (29092.9 nM) of CPT..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | PK095 is a proprietary compound in the guanidine - based F1F0-ATPase inhibitor family. |
| Molecular Weight | 378.45 |
| Formula | C20H18N4O2S |
| Cas No. | 380314-37-4 |
| Smiles | C(C)N1C=2C(C=3C1=CC=CC3)=CC(NC(CSC=4NC(=O)C=CN4)=O)=CC2 |
| Relative Density. | 1.38 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.79 mg/mL (10.01 mM), Sonication is recommended.  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PK095 | purchase PK095 | PK095 cost | order PK095 | PK095 chemical structure | PK095 formula | PK095 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.